After 10 years of treatment, Merck's Fosamax continued to work to increase bone density in post-menopausal women, even five years after they had stopped taking the drug, according to a new report. The trial was said to be the longest one conducted for prevention of the bone disease and appeared to offer an alternative for women afraid to take now-controversial hormone-replacement therapy.

Related Summaries